Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

Hepatol Int. 2024 Apr;18(2):384-419. doi: 10.1007/s12072-023-10633-7. Epub 2024 Feb 24.


Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.

Keywords: Diagnosis; Drug; Guideline; Herbal and dietary supplements; Liver injury; Management; Phenotypes; Prevention; Prognosis; Treatment.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents*
  • Chemical and Drug Induced Liver Injury* / diagnosis
  • Chemical and Drug Induced Liver Injury* / therapy
  • China
  • Humans
  • Liver Failure, Acute*
  • Risk Factors


  • Antineoplastic Agents